Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

医学 卡培他滨 胆囊癌 胰腺癌 放射治疗 胆道癌 外科 内科学 胆道 随机对照试验 结直肠癌 癌症 吉西他滨
作者
John N Primrose,Richard Fox,Daniel H. Palmer,Hassan Malik,Rajendra K. Prasad,Darius Mirza,Alan Anthony,Pippa G. Corrie,Stephen J. Falk,Meg Finch-Jones,Harpreet Singh Wasan,Paul J. Ross,Lucy R. Wall,Jonathan Wadsley,JEFF EVANS,Deborah D. Stocken,Raaj Praseedom,Yuk Ting Ma,Brian Ritchie Davidson,John P. Neoptolemos
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (5): 663-673 被引量:1326
标识
DOI:10.1016/s1470-2045(18)30915-x
摘要

Background Despite improvements in multidisciplinary management, patients with biliary tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection with curative intent, with 5-year overall survival of less than 10% for all patients. To our knowledge, no studies have described a benefit of adjuvant therapy. We aimed to determine whether adjuvant capecitabine improved overall survival compared with observation following surgery for biliary tract cancer. Methods This randomised, controlled, multicentre, phase 3 study was done across 44 specialist hepatopancreatobiliary centres in the UK. Eligible patients were aged 18 years or older and had histologically confirmed cholangiocarcinoma or muscle-invasive gallbladder cancer who had undergone a macroscopically complete resection (which includes liver resection, pancreatic resection, or, less commonly, both) with curative intent, and an Eastern Cooperative Oncology Group performance status of less than 2. Patients who had not completely recovered from previous surgery or who had previous chemotherapy or radiotherapy for biliary tract cancer were also excluded. Patients were randomly assigned 1:1 to receive oral capecitabine (1250 mg/m2 twice daily on days 1–14 of a 21-day cycle, for eight cycles) or observation commencing within 16 weeks of surgery. Treatment was not masked, and allocation concealment was achieved with a computerised minimisation algorithm that stratified patients by surgical centre, site of disease, resection status, and performance status. The primary outcome was overall survival. As prespecified, analyses were done by intention to treat and per protocol. This study is registered with EudraCT, number 2005-003318-13. Findings Between March 15, 2006, and Dec 4, 2014, 447 patients were enrolled; 223 patients with biliary tract cancer resected with curative intent were randomly assigned to the capecitabine group and 224 to the observation group. The data cutoff for this analysis was March 6, 2017. The median follow-up for all patients was 60 months (IQR 37–60). In the intention-to-treat analysis, median overall survival was 51·1 months (95% CI 34·6–59·1) in the capecitabine group compared with 36·4 months (29·7–44·5) in the observation group (adjusted hazard ratio [HR] 0·81, 95% CI 0·63–1·04; p=0·097). In a protocol-specified sensitivity analysis, adjusting for minimisation factors and nodal status, grade, and gender, the overall survival HR was 0·71 (95% CI 0·55–0·92; p=0·010). In the prespecified per-protocol analysis (210 patients in the capecitabine group and 220 in the observation group), median overall survival was 53 months (95% CI 40 to not reached) in the capecitabine group and 36 months (30–44) in the observation group (adjusted HR 0·75, 95% CI 0·58–0·97; p=0·028). In the intention-to-treat analysis, median recurrence-free survival was 24·4 months (95% CI 18·6–35·9) in the capecitabine group and 17·5 months (12·0–23·8) in the observation group. In the per-protocol analysis, median recurrence-free survival was 25·9 months (95% CI 19·8–46·3) in the capecitabine group and 17·4 months (12·0–23·7) in the observation group. Adverse events were measured in the capecitabine group only, and of the 213 patients who received at least one cycle, 94 (44%) had at least one grade 3 toxicity, the most frequent of which were hand-foot syndrome in 43 (20%) patients, diarrhoea in 16 (8%) patients, and fatigue in 16 (8%) patients. One (<1%) patient had grade 4 cardiac ischaemia or infarction. Serious adverse events were observed in 47 (21%) of 223 patients in the capecitabine group and 22 (10%) of 224 patients in the observation group. No deaths were deemed to be treatment related. Interpretation Although this study did not meet its primary endpoint of improving overall survival in the intention-to-treat population, the prespecified sensitivity and per-protocol analyses suggest that capecitabine can improve overall survival in patients with resected biliary tract cancer when used as adjuvant chemotherapy following surgery and could be considered as standard of care. Furthermore, the safety profile is manageable, supporting the use of capecitabine in this setting. Funding Cancer Research UK and Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
linkey完成签到,获得积分10
1秒前
要奋斗的小番茄完成签到,获得积分10
1秒前
赵佳雨完成签到 ,获得积分10
3秒前
韭黄完成签到,获得积分10
4秒前
JingP完成签到,获得积分10
6秒前
王kk完成签到 ,获得积分10
6秒前
sll完成签到 ,获得积分10
10秒前
白锎水完成签到 ,获得积分10
13秒前
孙文远完成签到,获得积分10
13秒前
刘先生完成签到 ,获得积分10
14秒前
luckweb完成签到,获得积分10
14秒前
韭菜完成签到,获得积分10
15秒前
105完成签到 ,获得积分0
15秒前
15秒前
疯狂乱跳的脉搏完成签到 ,获得积分10
17秒前
luckweb发布了新的文献求助10
18秒前
哎呀完成签到 ,获得积分20
19秒前
xinL完成签到,获得积分10
19秒前
易翼完成签到,获得积分10
20秒前
充电宝的应助被温暖静柏采纳,获得10
22秒前
Candice完成签到,获得积分10
22秒前
KK完成签到,获得积分10
22秒前
完犊子完成签到,获得积分10
25秒前
幸福雨完成签到 ,获得积分10
26秒前
安静的ky完成签到,获得积分10
26秒前
matafeiyan完成签到,获得积分10
27秒前
YAYING完成签到 ,获得积分10
28秒前
零距离完成签到,获得积分10
29秒前
ddzzgz完成签到 ,获得积分10
30秒前
31秒前
33秒前
迷路柠檬完成签到 ,获得积分10
33秒前
卡云上完成签到,获得积分10
36秒前
韭菜盒子完成签到,获得积分10
36秒前
372925abc完成签到,获得积分10
36秒前
Hello的应助被chic采纳,获得20
38秒前
王旭倩完成签到 ,获得积分10
39秒前
Lily完成签到,获得积分10
40秒前
凌风苇岸完成签到 ,获得积分10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370